Reig Jofre's profit falls by 52% to 4.99 million euros
The company earned 331.1 million, 2% less due to the drop in antibiotic sales caused by temporary shutdowns at its Toledo plant.
BarcelonaThe Catalan pharmaceutical company Reig Jofre closed 2025 with a net profit of €4.99 million, 52% less than the previous year due to temporary production shutdowns and a 30% drop in antibiotic sales. In total, the majority family-owned group obtained revenues of €331.1 million, 2% less than in 2024. The year was marked by the company's industrial transformation. At the Toledo plant, planned shutdowns and the renovation of two antibiotic production lines were carried out in a context of recovering demand for oral antibiotics after the exceptional increases during the pandemic. Investments in the sterile area continued at the Barcelona plant. The company also integrated Leanbioand, therefore, Syna Therapeutics, which they had previously formed jointly.
The decline in antibiotics, which in 2024 accounted for 20% of the business, could not be fully offset by the growth in injectables, from the division of Specialty Pharmacare, which advanced 4%, and the business of Consumer Healthcarewhich increased by 3%. Operating profit (EBITDA) stood at 30.5 million, weighed down mainly by the temporary reduction in capacity in Toledo, whose impact the company estimates at approximately 10 million euros.
Last year, the group invested €34 million. Industrial investments totaled €21.2 million; development investments, €5.1 million; and digitalization investments, €3.5 million, as well as those allocated to the stake in Leanbio. The total assets acquired by Syna Therapeutics and Leanbio amount to €47 million. Industrial investment was concentrated in Toledo, to improve productivity and ensure regulatory compliance for antibiotics, and in Barcelona, with the development of the new injectable and lyophilized product line and the upgrade of the sterile area, with commissioning expected in the second quarter of the current fiscal year.
By 2025, Reig Jofre has reinforced its focus on areas with greater value-generating potential, such as injectables, biotechnology, private label brands, and innovation. This is being achieved by combining industrial execution, advancing the new product portfolio, and "strengthening capabilities, with science and quality as the differentiating factors of the model," according to the company.